Source: EURLEX
Language: en
Format: md

201805250431897002018/C 200/553542017TC20020180611EN01ENINFO\_JUDICIAL20180423424322

Case T-354/17: Judgment of the General Court of 23 April 2018 — Genomic Health v EUIPO (ONCOTYPE DX GENOMIC PROSTATE SCORE) (EU trade mark — Application for EU word mark ONCOTYPE DX GENOMIC PROSTATE SCORE — Absolute ground for refusal — Descriptiveness — Article 7(1)(c) of Regulation (EC) No 207/2009 (now Article 7(1)(c) of Regulation (EU) 2017/1001) — Equal treatment)

[Top](#document1)

C2002018EN4220120180423EN0055422432

Judgment of the General Court of 23 April 2018 — Genomic Health v EUIPO (ONCOTYPE DX GENOMIC PROSTATE SCORE)

(Case T-354/17) (
[1](#t-C_2018200EN.01004202-E0001)
)

‛(EU trade mark — Application for EU word mark ONCOTYPE DX GENOMIC PROSTATE SCORE — Absolute ground for refusal — Descriptiveness — Article 7(1)(c) of Regulation (EC) No 207/2009 (now Article 7(1)(c) of Regulation (EU) 2017/1001) — Equal treatment)’

2018/C 200/55Language of the case: English

Parties

Applicant: Genomic Health, Inc. (Redwood City, California, United States of America) (represented by: A. Reid, Solicitor)

Defendant: European Union Intellectual Property Office (represented by: J. Ivanauskas and K. Sidat Humphreys, acting as Agents)

Re:

Action brought against the decision of the Fifth Board of Appeal of EUIPO of 14 February 2017 (Case R 1682/2016-5), concerning an application for registration of the word sign ONCOTYPE DX GENOMIC PROSTATE SCORE as an EU trade mark.

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |

| 2. | Orders Genomic Health, Inc., to pay the costs. |

---

(
[1](#c-C_2018200EN.01004202-E0001)
) [OJ C 249, 31.7.2017](./../../../legal-content/EN/AUTO/?uri=OJ:C:2017:249:TOC).

[Top](#document2)